Enveric Biosciences (NASDAQ:ENVB) Stock Rating Upgraded by Wall Street Zen

Enveric Biosciences (NASDAQ:ENVB – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Enveric Biosciences presently has an average rating of “Sell”.

Get Enveric Biosciences alerts:

View Our Latest Stock Report on ENVB

Enveric Biosciences Stock Performance

ENVB traded down $0.08 during trading on Friday, reaching $1.35. The stock had a trading volume of 76,159 shares, compared to its average volume of 205,692. The stock has a market cap of $4.97 million, a PE ratio of -0.06 and a beta of 1.15. Enveric Biosciences has a one year low of $1.26 and a one year high of $17.64. The business has a 50-day moving average of $1.94 and a 200-day moving average of $2.58.

Enveric Biosciences (NASDAQ:ENVB – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($1.08) earnings per share (EPS) for the quarter.

Enveric Biosciences Company Profile

(Get Free Report)

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.

Further Reading

• Five stocks we like better than Enveric Biosciences
• 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
• Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
• Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
• This Dividend ETF Choice Could Shape Your Income Strategy Through 2026

Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.